前言

第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2日至6日举行。本届ASCO年会MM领域者重磅研究有哪些呢，一起来看看吧。

 

摘要号：8010—MM-CAR-T

标题：Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T: At least 5-year follow-up in LEGEND-2.

报告人：糜坚青

单位：上海交通大学医学院附属瑞金医院上海血液研究所、医学基因组学国家重点实验室

 

摘要号：8013-MM

标题：Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world experience from the US myeloma CAR T consortium.

报告人：Aimaz Afrough

单位：Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

 

摘要号：8017-MM

标题：Final results of pilot trial to evaluate anti-PD1 and 8 Gy in 1 fx for relapsed refractory multiple myeloma.

报告人：Mohammad Khan

单位：Emory University

 

摘要号：8020-MM

标题：Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.

报告人：Paula Rodríguez-Otero

单位：Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA

 

摘要号：8029-MM

标题：Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.

报告人：Khalid Shalaby

单位：Roswell Park Comprehensive Cancer Center

 

摘要号：8030-MM

标题：Phase 2 study of abatacept, ixazomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.

报告人：Khalid Shalaby

单位：Roswell Park Comprehensive Cancer Center

 

摘要号：8036-MM

标题：Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).

报告人：Carolina Schinke

单位：Myeloma Center, University of Arkansas for Medical Sciences

 

摘要号：8040—MM—药物疗效

标题：Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.

报告人：Noopur Raje

单位：Massachusetts General Hospital Cancer Center, Harvard Medical School

 

摘要号：8041—MM—给药

标题：Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.

报告人：Xuewen Ma

单位：Janssen Research & Development

 

摘要号：TPS8063

标题：A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).

报告人：Jesus Berdeja

单位：Sarah Cannon Research Institute

 

摘要号：TPS8068—新药--MM

标题：OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.

报告人：Dagmar Hess

单位：Kantonsspital St. Gallen

 

摘要号：TPS8070--MM

标题：A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.

报告人：Paul Richardson

单位：Dana-Farber Cancer Institute

Tags： 【ASCO 会议速递】多发性骨髓瘤领域重要研究汇总